**Question:** The following drug antagonizes the visceral side effects of neostigmine used for reversal of vecuronium blockade:

A. Atropine
B. Org 101725
C. Naloxone
D. Flumazenil

**Core Concept:**
Neostigmine is a cholinesterase inhibitor commonly used to reverse the neuromuscular blockade caused by vecuronium, a muscle relaxant. However, neostigmine also causes unwanted effects on the parasympathetic system, including salivation, bronchoconstriction, and gastrointestinal motility. These side effects can be managed with a suitable antagonist.

**Why the Correct Answer is Right:**
The correct answer, Atropine, is a muscarinic antagonist that inhibits the action of acetylcholine, thereby counteracting the effects of neostigmine. Atropine binds to muscarinic receptors, preventing the overstimulation of the parasympathetic system that leads to the side effects of neostigmine.

**Why Each Wrong Option is Incorrect:**
A. Org 101725 (Flumazenil): Flumazenil is a benzodiazepine antagonist, used to reverse the effects of benzodiazepines. It does not antagonize the side effects of neostigmine.

B. Naloxone: Naloxone is a narcotic antagonist used to reverse the effects of opioids. Like Flumazenil, it is not relevant to the management of neostigmine side effects.

C. Naloxone: As mentioned earlier, Naloxone is not the appropriate drug for antagonizing the side effects of neostigmine.

**Clinical Pearl:**
When using neostigmine to reverse neuromuscular blockade caused by vecuronium, it is crucial to balance the benefits of restoring muscle function against the potential side effects. Atropine is the appropriate choice to manage the unwanted muscarinic effects of neostigmine, ensuring a safer and more effective reversal of neuromuscular blockade without exacerbating these side effects.